礼来在研药物 retatrutide 头对头研究中降糖减重效果优于 Ozempic
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
礼来称，其研究性药物 retatrutide 在一项大型糖尿病研究中降低血糖和减轻体重的效果优于 Novo Nordisk 的 Ozempic。该消息由礼来于当日上午公布，具体数据未在可见正文中披露。
同一件事，精选收录的是《礼来 retatrutide 头对头 III 期 TRANSCEND-T2D-2 结果优于 Ozempic 2 mg》
Two deaths reported in cell therapy autoimmune trial, Epic’s dominance over patient data, and more biotech news
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got lots of news today to get into.
Lilly’s triple-G drug beats Ozempic in head-to-head study
Eli Lilly said this morning that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
National Biotech Reporter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.
来源：STAT News · statnews.com